SPTLC3

Across TCGA pan-cancer cohorts, SPTLC3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPTLC3 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPTLC3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPTLC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where SPTLC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.627	0.948	.007	23	view →
HNSC	DFS	Median	IV	0.880	0.594	.006	9	view →
LUAD	DFS	Tertile	All	0.911	0.501	.015	7	view →
GBM	DFS	Tertile	All	0.653	0.871	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPTLC3–LSCC (OS)

Open the LSCC breakdown →